AMGN · 10-Q · 2026Q3 · Full report
Capital Expenditures Program
AMGEN INC · 2026-11-04 · Importance 93 · Surprise 82 · No source text
Capital expenditures were $1.8 billion during the nine months ended September 30, 2026, compared with $1.2 billion in the same 2025 period. The spending primarily funded construction of new plants and manufacturing-capacity expansion. Amgen estimated full-year 2026 capital-project investments of approximately $2.6 billion. Cash used in investing activities was $1.934 billion for the nine months, compared with $1.250 billion in 2025.
Key facts
- Amgen estimates full-year 2026 investments in capital projects of approximately $2.6 billion. source
- Amgen capital expenditures were $1.8 billion in the nine months ended September 30, 2026, compared with $1.2 billion in the prior-year period, primarily for construction of new plants and manufacturing capacity expansion. source
- Amgen reported $1.8 billion of property, plant and equipment purchases during the nine months ended September 30, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -0.7% | Amgen estimates full-year 2026 investments in capital projects of approximately $2.6 billion. |
| cash | negative | realized | -0.6% | Amgen capital expenditures were $1.8 billion in the nine months ended September 30, 2026, compared with $1.2 billion in the prior-year… |